These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16673582)

  • 1. [Mutations of DNA gyrase and topoisomerase IV in clinical isolates of fluoroquinolone-resistant Proteus mirabilis].
    Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
    Jpn J Antibiot; 2006 Feb; 59(1):41-3. PubMed ID: 16673582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
    Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
    J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis.
    Weigel LM; Anderson GJ; Tenover FC
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2582-7. PubMed ID: 12121936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
    Lee JK; Lee YS; Park YK; Kim BS
    Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
    Korzheva N; Davies TA; Goldschmidt R
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
    Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
    J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in clinical strains of fluoroquinolone-resistant Shigella in Anhui, China.
    Hu LF; Li JB; Ye Y; Li X
    J Microbiol; 2007 Apr; 45(2):168-70. PubMed ID: 17483803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.
    Rafii F; Park M; Novak JS
    Antimicrob Agents Chemother; 2005 Feb; 49(2):488-92. PubMed ID: 15673722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 114 clinical isolates of Pseudomonas aeruginosa derived from urinary tract infections and their rapid detection by denaturing high-performance liquid chromatography.
    Matsumoto M; Shigemura K; Shirakawa T; Nakano Y; Miyake H; Tanaka K; Kinoshita S; Arakawa S; Kawabata M; Fujisawa M
    Int J Antimicrob Agents; 2012 Nov; 40(5):440-4. PubMed ID: 22884856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of gyrA and parC mutations in fluoroquinolones-resistant Pseudomonas aeruginosa isolates from Iran.
    Nouri R; Ahangarzadeh Rezaee M; Hasani A; Aghazadeh M; Asgharzadeh M
    Braz J Microbiol; 2016; 47(4):925-930. PubMed ID: 27522930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fluoroquinolone resistance mutations in topoisomerase genes of Salmonella typhimurium isolates].
    Guo Y; Pei X; Liu X
    Wei Sheng Yan Jiu; 2004 Sep; 33(5):591-4. PubMed ID: 15612489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
    Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
    J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolone resistance linked to both gyrA and parC mutations in the quinolone resistance-determining region of Shigella dysenteriae type 1.
    Talukder KA; Khajanchi BK; Islam MA; Islam Z; Dutta DK; Rahman M; Watanabe H; Nair GB; Sack DA
    Curr Microbiol; 2006 Feb; 52(2):108-11. PubMed ID: 16450072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA gyrase and topoisomerase IV mutations in an in vitro fluoroquinolone-resistant Coxiella burnetii strain.
    Vranakis I; Sandalakis V; Chochlakis D; Tselentis Y; Psaroulaki A
    Microb Drug Resist; 2010 Jun; 16(2):111-7. PubMed ID: 20438350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
    Canton R; Morosini M; Enright MC; Morrissey I
    J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of Type II Topoisomerase Mutations to Fluoroquinolone Resistance in Enterococcus faecium from Japanese Clinical Setting.
    Urushibara N; Suzaki K; Kawaguchiya M; Aung MS; Shinagawa M; Takahashi S; Kobayashi N
    Microb Drug Resist; 2018; 24(1):1-7. PubMed ID: 28504916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular mechanisms of fluoroquinolone resistance found in rectal swab isolates of Enterobacterales from men undergoing a transrectal prostate biopsy: the rationale for targeted prophylaxis.
    Piekarska K; Zacharczuk K; Wołkowicz T; Mokrzyś M; Wolaniuk N; Nowakowska M; Szempliński S; Dobruch J; Gierczyński R
    Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):81. PubMed ID: 34876123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of mutations in DNA gyrase and topoisomerase IV of Ureaplasma urealyticum and Ureaplasma parvum serovars resistant to fluoroquinolones.
    Piccinelli G; Gargiulo F; Biscaro V; Caccuri F; Caruso A; De Francesco MA
    Infect Genet Evol; 2017 Jan; 47():64-67. PubMed ID: 27884651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.